This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Prothipendyl is a neuroleptic agent indicated in the treatment of restlessness and agitation in patients with underlying psychiatric conditions.
- Generic Name
- Prothipendyl
- DrugBank Accession Number
- DB12958
- Background
Prothipendyl has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Prothipendyl (DB12958)
- Weight
- Average: 285.41
Monoisotopic: 285.129968798 - Chemical Formula
- C16H19N3S
- Synonyms
- Prothipendyl
- Prothipendylum
- Protipendilo
- External IDs
- AY 56031
- D 206
- LG 206
- MH 05101
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Psychomotor agitation •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Prothipendyl. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Prothipendyl. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Prothipendyl. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Prothipendyl. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Prothipendyl. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Prothipendyl hydrochloride 7610629RVH 1225-65-6 CQJSAKJMCVSEGU-UHFFFAOYSA-N Prothipendyl hydrochloride monohydrate 9G1ILH80SA 70145-94-7 YATJECIBCQMRMY-UHFFFAOYSA-N - International/Other Brands
- Dominal / Tumovan
Categories
- ATC Codes
- N05AX07 — Prothipendyl
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Amines
- Direct Parent
- Alkyldiarylamines
- Alternative Parents
- Diarylthioethers / Benzothiazines / Pyridines and derivatives / Imidolactams / Benzenoids / 1,4-thiazines / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds show 1 more
- Substituents
- Alkyldiarylamine / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Benzenoid / Benzothiazine / Diarylthioether / Heteroaromatic compound / Hydrocarbon derivative / Imidolactam show 6 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5O6VWA87VA
- CAS number
- 303-69-5
- InChI Key
- JTTAUPUMOLRVRA-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H19N3S/c1-18(2)11-6-12-19-13-7-3-4-8-14(13)20-15-9-5-10-17-16(15)19/h3-5,7-10H,6,11-12H2,1-2H3
- IUPAC Name
- dimethyl(3-{9-thia-2,4-diazatricyclo[8.4.0.0^{3,8}]tetradeca-1(14),3(8),4,6,10,12-hexaen-2-yl}propyl)amine
- SMILES
- CN(C)CCCN1C2=CC=CC=C2SC2=C1N=CC=C2
References
- General References
- DIMDI Drug Product Information: Dominal (prothipendyl hydrochloride) for oral use [Link]
- External Links
- PubChem Compound
- 14670
- PubChem Substance
- 347829098
- ChemSpider
- 14002
- 55244
- ChEBI
- 135182
- ChEMBL
- CHEMBL2111030
- ZINC
- ZINC000000001996
- Wikipedia
- Prothipendyl
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral 50 mg/mL Tablet, coated Oral 40 MG Tablet, film coated Oral 80 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.128 mg/mL ALOGPS logP 3.53 ALOGPS logP 3.31 Chemaxon logS -3.4 ALOGPS pKa (Strongest Basic) 9.2 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 19.37 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 87.11 m3·mol-1 Chemaxon Polarizability 32.44 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0c00-6390000000-6cc7936806d42f688af1 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-c7965e64a88aa72675b1 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0090000000-8281ec4ab9adc23fdb20 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-000l-2090000000-f5b19bf48378d8b079ad Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0390000000-c07dde81ef9332e26d42 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0zi9-4590000000-71157624d538c77396ea Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0920000000-af7459a8081ffc406d5b Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 176.0145433 predictedDarkChem Lite v0.1.0 [M-H]- 157.08006 predictedDeepCCS 1.0 (2019) [M+H]+ 176.2982433 predictedDarkChem Lite v0.1.0 [M+H]+ 159.43806 predictedDeepCCS 1.0 (2019) [M+Na]+ 176.2024433 predictedDarkChem Lite v0.1.0 [M+Na]+ 165.5312 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 01:35 / Updated at September 18, 2024 17:21